• Skip to primary navigation
  • Skip to main content
  • Skip to footer

LKT Labs

Biochemicals for Life Science Research

  • Products
    • New Products
    • Cancer Biology
    • Cardiovascular
    • Endocrine Signaling and Immunology
    • Metabolic and GI Pathology
    • Microbiology
    • Natural Products
    • Neuroscience
    • Peptides
    • Pharmaceutical Impurities and Derivatives
    • Stem Cell Modulators
  • Services
    • Custom Synthesis
    • Natural Product Isolation
    • Analytical Services
  • Int’l Distributors
  • Support
    • About LKT Labs
    • General Inquiry
    • Bulk Quote Request
    • Document Request
    • Technical Support
    • Catalog Request
    • Product Flyers
  • Contact Us
  • Cart
  • Login / Register
Dacomitinib Anhydrous

Dacomitinib Anhydrous

Product ID D004098
Cas No. 1110813-31-4
Purity ≥99%
Product Unit SizeCostQuantityStock
5 mg $61.40 In stock
25 mg $133.60 In stock
100 mg $402.00 In stock
Bulk Quote

Quicklinks

  • Description
  • Product Info
  • Shipping and Storage
  • Downloads
  • References
  • Description
  • Product Info
  • Shipping and Storage
  • Downloads
  • References
  • Custom Order

Description

Dacomitinib is a selective and irreversible inhibitor of EGFR. Compared to first generation EGFR inhibitors, dacomitinib shows increased efficacy in models of non-small cell lung cancer (NSCLC) cells. It also suppresses proliferation of pancreatic ductal adenocarcinoma cells.

Product Info

Cas No.

1110813-31-4

Purity

≥99%

Formula

C24H25ClFN5O2

Formula Wt.

469.95

IUPAC Name

(2E)-N-{4-[(3-Chloro-4-fluorophenyl)amino]-7-methoxy-6-quinazolinyl}-4-(1-piperidinyl)-2-butenamide

Synonym

PF00299804 Anhydrous

Melting Point

184-187°C

Solubility

DMSO 75 mg/mL Water <1 mg/mL Ethanol <1 mg/mL

Shipping and Storage

Store Temp

-20°C

Ship Temp

Ambient

Downloads

MSDS

D004098 MSDS PDF

Info Sheet

D004098 Info Sheet PDF

References

Gonzales A., Hook K., Antitumor activity and pharmacokinetic properties of PF-00299804, a second-generation irreversible pan-erbB receptor tyrosine kinase inhibitor. Mol Cancer Ther. 7(7):1880-9 (2008). PMID: 18606718.

Nagano T., Tachihara M., et al. Dacomitinib, a second-generation irreversible epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) to treat non-small cell lung cancer. Drugs Today (Barc). 55(4):231-236 (2019). PMID: 31050691.

Momeny M., Esmaeili F., et al. The ERBB receptor inhibitor dacomitinib suppresses proliferation and invasion of pancreatic ductal adenocarcinoma cells. Cell Oncol. 2019. PMID: 31025257.

Custom Order

  • Size of single unit expressed as number (e.g. '500' in the case of 500 mg)
  • Total quantity of unit size desired (e.g. '10' in the case of 10 x 500 mg). If only one unit is desired, you may leave this blank.
  • This field is for validation purposes and should be left unchanged.

Related Products

  • B3320

    Bifonazole

    Imidazole; HMG-CoA reductase, 14-α demethylase...

    ≥98%
  • F4857

    FMRF Amide

    Cardiostimulatory neuropeptide; delayed rectifi...

    ≥95%
  • A4940

    6-Aminonicotinamide

    G6PDH inhibitor.

    ≥98%
  • P698583

    Prostaglandin E2

    principal metabolic product of COX-2

    ≥98%
  • I0801

    IC261

    Casein kinase 1 inhibitor.

    ≥98%
  • L3551

    Limonin Glucoside

    Furanolactone found in Citrus.

    ≥95%
  • M1769

    Meropenem Trihydrate

    β-lactam carbapenem; penicillin binding protei...

    ≥98%
  • B1853

    1,4-Benzoquinone

    Precursor in the synthesis of hydroquinone, ant...

    ≥98%
  • T4800

    TM3-0089 Sodium Monohydrate

    CRTH2 inhibitor.

    ≥98%
  • G720009

    GS-9901

    Selective inhibitor of the delta isoform of PI3...

    ≥99%
  • S881011

    Swainsonine

    Antineoplastic immunomodulator.

    ≥98%
  • V344761

    Vitamin K2

    2-methyl-1,4-naphthoquinone derivative

    ≥98%
  • K5606

    Kobe 2602

    Ras inhibitor.

    ≥98%
  • A9912

    AZD-7762 Hydrochloride

    CHK1 inhibitor.

    ≥98%
  • P577520

    Ponatinib

    pan-Bcr-Abl tyrosine kinase inhibitor.

    ≥99%
  • G4532

    Gliclazide

    Sulfonylurea; SUR1 antagonist.

    ≥98%
  • A706840

    ARV-825

    Degrades of BET proteins.

    ≥99%
  • M9710

    Mycophenolic Acid

    Phthalide; PPARγ agonist, IMPDH inhibitor, mic...

    ≥98%
  • I5208

    INCB-28060

    c-MET inhibitor.

    ≥98%
  • S8044

    R,S-Sulforaphane, High Purity

    Phase II enzyme inducer; Nrf2 activator; antiox...

    ≥99%

Footer

  • Contact Us
  • About Us
  • Site Map
  • Terms and Conditions
LKT Laboratories, Inc.
545 Phalen Blvd.
St. Paul MN, 55130

Ph: (888)-558-5227
Fax: (888)-558-7329

©2025 LKT Laboratories, All Rights Reserved - Products for research use only